MorphoSys AG — Governance Information 2004

Jun 18, 2004

News Details

Corporate | 18 June 2004 07:44

MorphoSys Awarded for Corporate Governance Excellence

Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– Press Release Martinsried/Munich (Germany) June 18, 2004 MorphoSys Awarded for Corporate Governance Excellence MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard segment) announced today that the Company placed first among all Mid and Small Caps in this year’s Corporate Governance Survey conducted by the consultancy ergo Kommunikation. Additionally, in the overall classification, covering 210 German companies including the DAX, MDAX, SDAX and TecDax-listed companies, MorphoSys achieved fifth place, behind the four DAX-listed companies Altana, Deutsche Bank, Siemens and Deutsche Boerse, being the only non-DAX company that attained an “exemplary” grade. The survey, carried out annually, compares the degree of implementation of the German Corporate Governance Code and various other investor relations aspects, at companies listed in the above-mentioned indices in addition to 80 small caps from both the Prime and General Standard segments. A copy of the study can be found at http://www.ergo-pr.de . “We are pleased by the recognition of our efforts relating to the adoption of policies regarding corporate governance. Corporate governance has been and remains an important topic for MorphoSys”, stated Dave Lemus, Chief Financial Officer of MorphoSys AG. About ergo Kommunikation: ergo Unternehmenskommunikation GmbH & Co. KG is a leading communications consultancy in Germany and belongs to the Top 50 agencies in the fields of Investor and Public Relations. 30 professionals in Cologne and Frankfurt advise their clients in different industries such as financial services, international trading, manufacturing, consulting as well as the public authorities. ergo is listing partner of Deutsche Börse and member of a global network of independent PR agencies. About MorphoSys: MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company’s proprietary Human Combinatorial Antibody Library (HuCALâ) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Biogen Idec Inc. (Cambridge, Massachusetts/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (Wilmington, Delaware/USA), Centocor Inc. (Malvern, Pennsylvania/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Novartis AG (Cambridge, Massachusetts/USA), Oridis Biomed GmbH (Graz/Austria), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany) and Xoma Ltd. (Berkeley, California/USA). For further information please visit the corporate website at: http://www.morphosys.com/ . Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, “forward-looking statements” for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company’s proprietary rights and other factors described in the prospectus relating to the company’s recent public offering. For more information, please contact MorphoSys: Dave Lemus Chief Financial Officer Tel: +49 (0) 89 / 899 27-439 Fax: +49 (0) 89 / 899 27-5439 investors@morphosys.com Dr. Claudia Gutjahr-Löser Mario Brkulj Director Corporate Communications PR Specialist Tel: +49 (0) 89 / 899 27-122 Tel: +49 (0) 89 / 899 27-454 Fax: +49 (0) 89 / 899 27-5122 Fax: +49 (0) 89 / 899 27-5454 gutjahr-loeser@morphosys.com brkulj@morphosys.com end of message, (c)DGAP 18.06.2004 ——————————————————————————– WKN: 663200; ISIN: DE0006632003; Index: Nemax 50 Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 180744 Jun 04